|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0019196,
umls-concept:C0021734,
umls-concept:C0024501,
umls-concept:C0030705,
umls-concept:C0034656,
umls-concept:C0035525,
umls-concept:C0087111,
umls-concept:C0206012,
umls-concept:C0376196,
umls-concept:C0524910,
umls-concept:C1096776,
umls-concept:C1677789
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
2005-3-7
|
|
pubmed:abstractText |
Many intravenous opiate users are infected with hepatitis C virus (HCV) but few are treated. Although this complies with various guidelines, virtually no published evidence supports such a recommendation.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Feb
|
|
pubmed:issn |
0300-8126
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
33
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
25-9
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:15750756-Antiviral Agents,
pubmed-meshheading:15750756-Drug Therapy, Combination,
pubmed-meshheading:15750756-Female,
pubmed-meshheading:15750756-Hepatitis C, Chronic,
pubmed-meshheading:15750756-Humans,
pubmed-meshheading:15750756-Interferon-alpha,
pubmed-meshheading:15750756-Male,
pubmed-meshheading:15750756-Recombinant Proteins,
pubmed-meshheading:15750756-Ribavirin,
pubmed-meshheading:15750756-Substance Abuse, Intravenous
|
|
pubmed:year |
2005
|
|
pubmed:articleTitle |
Interferon alpha-2a plus ribavirin 1,000/1,200 mg versus interferon alpha-2a plus ribavirin 600 mg for chronic hepatitis C infection in patients on opiate maintenance treatment: an open-label randomized multicenter trial.
|
|
pubmed:affiliation |
Division of Infectious Diseases and Hospital Epidemiology, University Hospital, CH-8091 Zurich, Switzerland. milo.huber@usz.ch
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial,
Multicenter Study
|
